Cardurion Pharmaceuticals, Inc.
11
1
1
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
45.5%
5 terminated/withdrawn out of 11 trials
50.0%
-36.5% vs industry average
0%
0 trials in Phase 3/4
80%
4 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
A Phase 2 Study of CRD-4730 in CPVT
Role: lead
Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)
Role: lead
A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)
Role: lead
Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Role: lead
Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction
Role: lead
A Study of IMR-687 in Subjects With Beta Thalassemia
Role: lead
Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740
Role: lead
A Study of IMR-687 in Healthy Adult Volunteers
Role: lead
A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)
Role: lead
A Study of IMR-687 in Subjects With Sickle Cell Disease
Role: lead
Effectiveness of CRD-740 in Heart Failure
Role: lead
All 11 trials loaded